R&D Spotlight: CLYM116 and the IgAN Opportunity SEPTEMBER 29, 2025 © 2025 Climb Bio 1 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Climb Bio, Inc. ("Climb Bio"); expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug and CLYM116; the trial design for ...